Highlander Capital Management LLC Has $5.55 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Highlander Capital Management LLC lessened its stake in Amgen Inc. (NASDAQ:AMGNGet Rating) by 0.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,940 shares of the medical research company’s stock after selling 100 shares during the period. Amgen comprises about 2.6% of Highlander Capital Management LLC’s holdings, making the stock its 6th largest holding. Highlander Capital Management LLC’s holdings in Amgen were worth $5,547,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dixon Hughes Goodman Wealth Advisors LLC purchased a new position in shares of Amgen during the fourth quarter valued at approximately $26,000. Norwood Financial Corp bought a new stake in Amgen in the fourth quarter valued at $28,000. Landmark Wealth Management LLC bought a new stake in Amgen in the first quarter valued at $28,000. Industrial Alliance Investment Management Inc. bought a new stake in Amgen in the fourth quarter valued at $31,000. Finally, CKW Financial Group bought a new stake in Amgen in the first quarter valued at $31,000. Institutional investors own 79.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on AMGN shares. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, May 16th. Oppenheimer restated an “outperform” rating and set a $290.00 target price on shares of Amgen in a report on Friday, June 24th. BMO Capital Markets dropped their target price on shares of Amgen from $263.00 to $243.00 in a report on Thursday, April 28th. TheStreet cut shares of Amgen from a “b+” rating to a “c+” rating in a report on Wednesday, April 27th. Finally, Royal Bank of Canada boosted their target price on shares of Amgen from $224.00 to $236.00 in a report on Friday. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $250.00.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $246.25 on Friday. Amgen Inc. has a fifty-two week low of $198.64 and a fifty-two week high of $258.45. The business has a 50-day simple moving average of $245.14 and a two-hundred day simple moving average of $239.83. The company has a debt-to-equity ratio of 39.31, a quick ratio of 1.09 and a current ratio of 1.44. The firm has a market cap of $131.55 billion, a price-to-earnings ratio of 20.87, a price-to-earnings-growth ratio of 2.04 and a beta of 0.56.

Amgen (NASDAQ:AMGNGet Rating) last issued its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, topping analysts’ consensus estimates of $4.40 by $0.25. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.53 billion. Amgen had a return on equity of 188.78% and a net margin of 24.92%. Amgen’s revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.38 EPS. On average, analysts expect that Amgen Inc. will post 17.38 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th will be paid a dividend of $1.94 per share. The ex-dividend date is Wednesday, August 17th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.15%. Amgen’s dividend payout ratio is currently 65.76%.

Insider Buying and Selling at Amgen

In other Amgen news, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction dated Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares in the company, valued at approximately $1,375,250. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director R Sanders Williams sold 600 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 5,501 shares in the company, valued at approximately $1,375,250. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $241.81, for a total value of $3,264,435.00. Following the transaction, the executive vice president now owns 37,333 shares of the company’s stock, valued at $9,027,492.73. The disclosure for this sale can be found here. Corporate insiders own 0.46% of the company’s stock.

Amgen Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Recommended Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.